356 related articles for article (PubMed ID: 20675713)
1. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies.
Chan YM; Keramaris-Vrantsis E; Lidov HG; Norton JH; Zinchenko N; Gruber HE; Thresher R; Blake DJ; Ashar J; Rosenfeld J; Lu QL
Hum Mol Genet; 2010 Oct; 19(20):3995-4006. PubMed ID: 20675713
[TBL] [Abstract][Full Text] [Related]
2. Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes.
Blaeser A; Keramaris E; Chan YM; Sparks S; Cowley D; Xiao X; Lu QL
Hum Genet; 2013 Aug; 132(8):923-34. PubMed ID: 23591631
[TBL] [Abstract][Full Text] [Related]
3. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
4. Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.
Kim J; Hopkinson M; Kavishwar M; Fernandez-Fuente M; Brown SC
Skelet Muscle; 2016; 6():3. PubMed ID: 26900448
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions.
Xu L; Lu PJ; Wang CH; Keramaris E; Qiao C; Xiao B; Blake DJ; Xiao X; Lu QL
Mol Ther; 2013 Oct; 21(10):1832-40. PubMed ID: 23817215
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies.
Ackroyd MR; Skordis L; Kaluarachchi M; Godwin J; Prior S; Fidanboylu M; Piercy RJ; Muntoni F; Brown SC
Brain; 2009 Feb; 132(Pt 2):439-51. PubMed ID: 19155270
[TBL] [Abstract][Full Text] [Related]
7. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
[TBL] [Abstract][Full Text] [Related]
8. Restoration of Functional Glycosylation of α-Dystroglycan in FKRP Mutant Mice Is Associated with Muscle Regeneration.
Awano H; Blaeser A; Keramaris E; Xu L; Tucker J; Wu B; Lu P; Lu QL
Am J Pathol; 2015 Jul; 185(7):2025-37. PubMed ID: 25976249
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish models for human FKRP muscular dystrophies.
Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
[TBL] [Abstract][Full Text] [Related]
10. Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP).
Thornhill P; Bassett D; Lochmüller H; Bushby K; Straub V
Brain; 2008 Jun; 131(Pt 6):1551-61. PubMed ID: 18477595
[TBL] [Abstract][Full Text] [Related]
11. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.
Qiao C; Wang CH; Zhao C; Lu P; Awano H; Xiao B; Li J; Yuan Z; Dai Y; Martin CB; Li J; Lu Q; Xiao X
Mol Ther; 2014 Nov; 22(11):1890-9. PubMed ID: 25048216
[TBL] [Abstract][Full Text] [Related]
12. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
[TBL] [Abstract][Full Text] [Related]
13. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
14. The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.
Whitmore C; Fernandez-Fuente M; Booler H; Parr C; Kavishwar M; Ashraf A; Lacey E; Kim J; Terry R; Ackroyd MR; Wells KE; Muntoni F; Wells DJ; Brown SC
Hum Mol Genet; 2014 Apr; 23(7):1842-55. PubMed ID: 24234655
[TBL] [Abstract][Full Text] [Related]
15. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
Cataldi MP; Lu P; Blaeser A; Lu QL
Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
[TBL] [Abstract][Full Text] [Related]
17. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
Elife; 2021 Jan; 10():. PubMed ID: 33513091
[TBL] [Abstract][Full Text] [Related]
18. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.
Godfrey C; Clement E; Mein R; Brockington M; Smith J; Talim B; Straub V; Robb S; Quinlivan R; Feng L; Jimenez-Mallebrera C; Mercuri E; Manzur AY; Kinali M; Torelli S; Brown SC; Sewry CA; Bushby K; Topaloglu H; North K; Abbs S; Muntoni F
Brain; 2007 Oct; 130(Pt 10):2725-35. PubMed ID: 17878207
[TBL] [Abstract][Full Text] [Related]
19. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
[TBL] [Abstract][Full Text] [Related]
20. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
